CD20 expression is associated with inferior survival in adults with ALL. We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated on three consecutive St. Jude Total Therapy studies. CD20 expression (>20%) was found in 169 patients (48%), and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years (p=0.001). None of 14 patients with MLL-AF4 expressed CD20. There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, WBC at diagnosis, or gender. In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better treatment outcome than those without the expression: 5-year event free survival 84% + 2.9% versus 78% + 3.1% (p=0.08). This data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.
INTRODUCTION
As intensification of acute lymphoblastic leukemia (ALL) chemotherapy is reaching a limit, targeted therapy may further improve treatment outcome by increasing the efficacy and decreasing the toxicity of standard regimens. In an effort to improve the outcome of adult ALL, a disease with 60% failure rate, investigators are exploring the benefits of combining targeted therapy to standard chemotherapy regimens. Incorporating imatinib mesylate, an inhibitor of the BCR-ABL tyrosine kinase, into the hyper-CVAD regimen for adult ALL with t (9;22) has improved the outcome of this population compared to that For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From of patients previously treated with hyper-CVAD alone 1 . Imatinib has now also been integrated into treatment regimens for pediatric Philadelphia chromosome-positive ALL.
Rituximab is a chimeric monoclonal antibody to CD20 which is expressed on normal and malignant B-lymphocytes. Favorable experience has been reported for the use of rituximab in combination with chemotherapy in mature B-cell lymphoma and leukemia. 2, 3 Because CD20 expression was associated with poor prognosis in adult ALL, the M.D. Anderson Cancer Center group incorporated rituximab in the treatment regimens for adults with B-cell precursor ALL. In the Anderson Cancer Center study in which the hyper-CVAD regimen was modified to incorporate rituximab for patients expressing CD20, one year disease free survival was 100% for CD20-positive patients (compared to 49% for similar patients treated on the original hyper-CVAD regimen, p=0.03) and 61% for CD20-negative patients 4 . Follow up at 2 years disclosed a disease free survival of 73% for the 27 patients with CD20-positive ALL treated with rituximab compared to 40% for the 36 patients with CD20-negative ALL (p=0.04) 5 To determine the prognostic impact of CD20 expression in pediatric patients with B-cell precursor ALL and the potential utility of rituximab in this subset of patients, we studied 353 children with B-cell precursor ALL treated at St. Jude Children's Research Hospital. Immunophenotypring, cytogenetic and molecular genetic analysis were performed with methods as previously reported 7 . Survival and event-free survival were analyzed using the Kaplan-Meier method 9 with the associated standard errors calculated using the method of Peto and Pike 10 . Survival comparisons were done by the Mantel-Haenszel test 11 . Cumulative incidences of any relapse observed in the cohort were analyzed using
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Gray's estimator with incorporation of second malignancies and death in remission as competing risks 12 . Chi-square tests were used to test association among categorical variables. All patients reported have signed IRB reviewed informed consents as per institutional policy and federal laws requirements.
RESULTS AND DISCUSSION
Of 353 children with B-cell precursor ALL, 169 (48%) expressed CD20 (>20%). As shown in Table 1 , children between 1 and 10 years were more likely to express CD20 as compared to infants less than 1 year of age or patients more than 10 year old (p=0.001).
African American patients were more likely to express CD20, as compared to Caucasians or other ethnic groups (p=0.02). None of 14 patients with MLL-AF4 expressed CD20 (p<0.001). The expression was detected in 71% of the 14 patients with BCR-ABL rearrangement and 47% of the 159 patients lacking BCR-ABL (p=0.07). A higher frequency of CD20 expression was noted in patients with liver > 5 cm (p=0.001) and those with spleen > 5 cm (p=0.02) compared to patients with liver and spleen less than 5
cm. There was no association between CD20 expression and gender, white blood cell count at diagnosis, E2A-PBX, TEL-AML1, or ploidy.
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In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better outcome than those without the expression (Figure 1 ): 5-year event free survival 84% + 2.9% versus 78% + 3.1% (p=0.08); 5-year overall survival 88% + 2.5% versus 83% + 2.8% (p=0.13). In a multivariate analysis adjusting for the effect of other prognostic factors, CD20 expression was not an independent prognostic factor for overall survival (p=0.27) or event free survival (p=0.16). However, patients with CD20 expression appeared to be less likely to have induction failure due to refractory leukemia or relapse (p=0.05), as shown in Table 1 This data suggest that CD20 expression is not an adverse prognostic factor in children with ALL treated on St Jude protocols. It remains to be determined whether modification 
